Show simple item record

dc.contributor.authorDrinkut, A
dc.contributor.authorTillack, K
dc.contributor.authorMeka, DP
dc.contributor.authorSchulz, JB
dc.contributor.authorKügler, S
dc.contributor.authorKramer, Edgar
dc.date.accessioned2017-08-11T10:10:23Z
dc.date.available2017-08-11T10:10:23Z
dc.date.issued2016-09-08
dc.identifier.issn2041-4889
dc.identifier.issn2041-4889
dc.identifier.otherARTN e2359
dc.identifier.urihttp://hdl.handle.net/10026.1/9770
dc.description.abstract

<jats:title>Abstract</jats:title><jats:p>Glial cell line-derived neurotrophic factor (GDNF) is a potent survival and regeneration-promoting factor for dopaminergic neurons in cell and animal models of Parkinson disease (PD). GDNF is currently tested in clinical trials on PD patients with so far inconclusive results. The receptor tyrosine kinase Ret is the canonical GDNF receptor, but several alternative GDNF receptors have been proposed, raising the question of which signaling receptor mediates here the beneficial GDNF effects. To address this question we overexpressed GDNF in the striatum of mice deficient for Ret in dopaminergic neurons and subsequently challenged these mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Strikingly, in this established PD mouse model, the absence of Ret completely abolished GDNF’s neuroprotective and regenerative effect on the midbrain dopaminergic system. This establishes Ret signaling as absolutely required for GDNF’s effects to prevent and compensate dopaminergic system degeneration and suggests Ret activation as the primary target of GDNF therapy in PD.</jats:p>

dc.format.extente2359-e2359
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherSpringer Science and Business Media LLC
dc.subjectAnimals
dc.subjectDisease Models, Animal
dc.subjectDopaminergic Neurons
dc.subjectGene Expression
dc.subjectGlial Cell Line-Derived Neurotrophic Factor
dc.subjectHumans
dc.subjectInjections, Intraventricular
dc.subjectMale
dc.subjectMesencephalon
dc.subjectMice
dc.subjectMice, Knockout
dc.subjectNeostriatum
dc.subjectNeuroprotective Agents
dc.subjectParkinson Disease
dc.subjectProto-Oncogene Proteins c-ret
dc.subjectSignal Transduction
dc.subjectStereotaxic Techniques
dc.subjectSubstantia Nigra
dc.titleRet is essential to mediate GDNF’s neuroprotective and neuroregenerative effect in a Parkinson disease mouse model
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000387968100008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue9
plymouth.volume7
plymouth.publication-statusPublished
plymouth.journalCell Death and Disease
dc.identifier.doi10.1038/cddis.2016.263
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeEngland
dcterms.dateAccepted2016-06-20
dc.identifier.eissn2041-4889
dc.rights.embargoperiodNo embargo
rioxxterms.versionofrecord10.1038/cddis.2016.263
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-09-08
rioxxterms.typeJournal Article/Review
plymouth.oa-locationhttps://www.nature.com/cddis/journal/v7/n9/full/cddis2016263a.html


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV